National Bank of Canada FI Boosts Stock Holdings in Amedisys, Inc. (NASDAQ:AMED)

National Bank of Canada FI grew its stake in shares of Amedisys, Inc. (NASDAQ:AMED - Free Report) by 33.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 74,400 shares of the health services provider's stock after acquiring an additional 18,808 shares during the quarter. National Bank of Canada FI owned about 0.23% of Amedisys worth $6,755,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of AMED. Blue Trust Inc. grew its position in Amedisys by 55.1% during the 4th quarter. Blue Trust Inc. now owns 349 shares of the health services provider's stock worth $34,000 after purchasing an additional 124 shares during the last quarter. HBW Advisory Services LLC acquired a new stake in shares of Amedisys during the fourth quarter worth $38,000. Versant Capital Management Inc grew its holdings in shares of Amedisys by 68.5% during the fourth quarter. Versant Capital Management Inc now owns 450 shares of the health services provider's stock valued at $41,000 after buying an additional 183 shares during the last quarter. Vestcor Inc acquired a new position in shares of Amedisys in the 4th quarter valued at $73,000. Finally, Venturi Wealth Management LLC raised its stake in Amedisys by 397.4% in the 4th quarter. Venturi Wealth Management LLC now owns 975 shares of the health services provider's stock worth $89,000 after acquiring an additional 779 shares during the last quarter. Institutional investors and hedge funds own 94.36% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, Stephens reiterated an "equal weight" rating and set a $101.00 price target on shares of Amedisys in a research note on Tuesday, March 4th. Four investment analysts have rated the stock with a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $101.00.

Remove Ads

Amedisys Stock Performance

Shares of AMED stock traded up $0.01 during trading hours on Friday, hitting $91.51. The company's stock had a trading volume of 302,927 shares, compared to its average volume of 400,964. The stock has a market cap of $3.00 billion, a PE ratio of 36.31, a price-to-earnings-growth ratio of 1.78 and a beta of 0.89. Amedisys, Inc. has a 12-month low of $82.15 and a 12-month high of $98.95. The company has a 50 day moving average of $92.20 and a 200 day moving average of $92.05. The company has a current ratio of 1.19, a quick ratio of 1.19 and a debt-to-equity ratio of 0.05.

Amedisys (NASDAQ:AMED - Get Free Report) last posted its earnings results on Wednesday, February 26th. The health services provider reported $0.96 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.05 by ($0.09). The business had revenue of $598.05 million for the quarter, compared to analyst estimates of $602.38 million. Amedisys had a net margin of 3.57% and a return on equity of 12.20%. On average, sell-side analysts forecast that Amedisys, Inc. will post 4.4 EPS for the current fiscal year.

Amedisys Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.